BY SIDNEY

GOLDSTEIN, M.D.

#### IN THIS ISSUE-

### 2 News

**Heart of the Matter** 

New COX-2 safety data yield more questions than answers, 8

#### **Imaging**

Hybrid PET/CT camera offers one-stop cardiac imaging.

#### 10 Interventional Cardiology

Door-to-balloon time is long in women with acute ST-segment elevation myocardial infarction.

#### 12 Acute Coronary Syndromes Low-molecular-weight heparin

# improves outcomes in acute MI. 14 Heart Failure

# Rheumatoid arthritis patients are at increased risk for heart failure.

### Arrhythmias & Electrophysiology

European guidelines recommend prescreening athletes with 12-lead

#### 17 CAD & Atherosclerosis

**Pro & Con:** Should men over age 40 be screened for coronary artery disease? Dr. Daniel S. Berman says yes; Dr. Raymond J. Gibbons says no. Niacin or psyllium fiber can augment the effectiveness of statins, 18

#### 19 Surgery

Left ventricular suturing can reduce volume in patients with cardiomyopathy.

#### 20 Practice Trends

Malpractice liability and the Medicare payment system are priorities for reform in 2005.

Policy & Practice, 22

23 On the Beat

## **Reader Services**

Classifieds, 21

Index of Advertisers, 23

### EDITORIAL ADVISORY BOARD

SIDNEY GOLDSTEIN, M.D., Michigan Medical Editor

JONATHAN ABRAMS, M.D., New Mexico Associate Medical Editor

ERIC R. BATES, M.D., Michigan

GEORGE BELLER, M.D., Virginia

STEVEN F. BOLLING, M.D., Michigan

ROBERT M. CALIFF, M.D., North Carolina

KIM A. EAGLE, M.D., Michigan

JOHN FLACK, M.D., Michigan

THOMAS D. GILES, M.D., Louisiana

ANTONIO M. GOTTO, Jr., M.D., New York DAVID L. HAYES, M.D., Minnesota

DAVID R. HOLMES, Jr., M.D., Minnesota

DONALD HUNNINGHAKE, M.D., Minnesota

BARRY M. MASSIE, M.D., California

CHRISTOPHER M. O'CONNOR, M.D., North Carolina

NATESA G. PANDIAN, M.D., Massachusetts ILEANA L. PIÑA, M.D., Ohio

OTELIO RANDALL, M.D., Washington, D.C.

THOMAS J. RYAN, M.D., Massachusetts

HANI N. SABBAH, Ph.D., Michigan

LESLIE ANNE SAXON. M.D., California

DAVID H. SPODICK, M.D., Massachusetts

ROBERTA WILLIAMS, M.D., California

# HEART OF THE MATTER

# The Quandary That Is Called the FDA

n the wake of the Vioxx scandal, the in order to expedite drug approval and Food and Drug Administration has become the whipping boy of the press, Congress, and even agency.

This column has not been lacking in

criticism of the FDA. We have expressed concern about some of its premature decisions and lack of postapproval surveillance of drugs. Nevertheless, let's place some of the blame where it should be placed. The FDA, created in 1906 as part of the Pure Food and Drug Act, has responded to changes in both the industry that it is intended to control and in the human beings

it is expected to protect. In its nearly 100 years of life, drugs have become more complex and Americans have grown older. Advances in technology and pharmacology in the last half century have provided physicians and patients a breathtaking array of medical options to prolong and improve the quality of life. But these products have the potential to harm those individuals who are the treatment targets.

It was but a short 12 years ago that Congress pressured the FDA to get in bed with the pharmaceutical industry

Editor-in-Chief Mary Jo M. Dales

S. Lesney, Jennifer Silverman

Wood

Publication Editor Catherine Hackett

Senior Editors Kathryn DeMott, Denise Fulton,

Lassman, Catherine Cooper Nellist, Calvin

Associate Editors Christina Chase, Richard

Bureaus Betsy Bates (Los Angeles), Sherry

Boschert (San Francisco), Doug Brunk (San

Diego), Robert Finn (San Francisco), Bruce

Jancin (Denver), Kate Johnson (Montreal),

MacReady (Los Angeles), Diana Mahoney (New

Walsh (New York), Patrice Wendling (Chicago),

Senior Writers Jeff Evans, Kevin Foley, Deeanna

Timothy F. Kirn (Sacramento), Norra

England), Damian McNamara (Miami),

Zoler (Philadelphia)

Moon, Carl Sherman

Copy Chief Felicia R. Black

Kerri Wachter

Locastro

Michele G. Sullivan (Mid-Atlantic), Nancy

Sharon Worcester (Tallahassee), Mitchel L.

Franklin, Elizabeth Mechcatie, Mary Ellen

Schneider, Heidi Splete, Miriam E. Tucker,

Contributing Writers Alicia Ault, Christine

Kilgore, Jane Salodof MacNeil, Mary Ann

Copy Editors John R. Bell, Therese Borden,

Virginia Ingram-Wells, Rachel Keith, Jane

Franki, Joyce Frieden, Gwendolyn Hall, Mark

Gina L. Henderson, Sally Koch Kubetin, Teresa

Pierce, Kathy Scarbeck, Terry Rudd, Elizabeth

get new drugs to market faster by collecting user fees from applicants. As a result of this and other initiatives, the approval of new molecular entities in-

creased from 30 in 1991 to 53 in 1996. But in order to maintain that pharmaceutical support, other programs had to be cut over time. Now, Congress charges that the FDA has been too hasty and superficial with their drug approval process.

As medical therapy has changed in the last half century, so to has the role of the FDA. Mid-20th-century medical therapy was

focused on the treatment of episodic short-term diseases like pneumonia. Safety and efficacy could be measured in days or weeks. Major advances occurred in the 1970s and 1980s that led to the consideration of drugs for the long-term prevention and treatment of chronic diseases that affect an increasingly aging population. Clinical trials suggested that drugs should be taken for a lifetime, and that can be a very long time when therapy was initiated in the midlife or even earlier. These randomized clinical trials, at best, provided information over 1-2 years of therapy and were tested in very unique populations. We have little knowledge of the effects of taking drugs for longer periods and even less information when the drugs are applied to broader and unselected populations. Numerous misadventures emerged. Vioxx (rofecoxib) can be added to a long list of drugs that were not fully investigated prior to their release.

It is therefore critical that we develop methodologies to understand the efficacy and safety of drugs and devices after initial short-term approval.

Some have suggested that we develop a two-track approval process in which drug efficacy and safety are established for a short term, at the same time establishing a surveillance system to monitor the long-term drug safety. The FDA is the proper environment to carry out this mission, but it needs to have Congressional support to make it happen. The Vioxx experience should provide the motivation necessary to achieve this long delayed effort.

DR. GOLDSTEIN, medical editor of CARDIOLOGY NEWS, is professor of medicine at Wayne State University, Detroit, and division head, emeritus, of cardiovascular medicine at Henry Ford Hospital, Detroit.

President, Elsevier/IMNG

Director, Operations James D. Chicca

Director, Production/Manufacturing Yvonne Evans

Production Manager Judi Sheffer Production Specialists Anthony Draper, Rebecca Slebodnik, Mary D. Templin

Senior Systems Administrator Lee J. Unger Application Systems Specialist Doug Sullivan **Operations Assistant** Melissa Kasimatis

Art Director Louise A. Koenig Assistant Design Supervisor Elizabeth B. Lobdell Design Staff Forhad S. Hossain, Julie Keller, Angie Ries

Photo Editors Vivian E. Lee, James E. Reinaker

Project Manager Susan D. Hite Assignments Coordinator Megan Evans

H.R. Manager Philip Cooksey

Regional Manager of Facilities Chris Horne Receptionist YoLanda L. Mitchell

Departmental Coordinator Vicki Long

CARDIOLOGY NEWS is an independent newspaper that provides the practicing specialist with timely and relevant news and commentary about clinical developments in the field and about the impact of health care policy on the specialty and the physician's practice.

The ideas and opinions expressed in CARDIOLOGY NEWS do not necessarily reflect those of the Publisher. Elsevier Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

V.P., Med. Ed./Bus. Development

Sylvia H. Reitman

Senior Director, Marketing/Research Janice Theobald

Program Managers, Med. Ed. Sara M. Hagan, Margo Ullmann

Sales Director Jeffrey R. Davis

Sales Manager, Primary Care Mark E. Altier National Account Manager Barbara Napoli Classified Sales Manager Robin Cryan

Director, Bus. Operations/Recruit. Adv. Bari Edwards Bus. Manager Brian O'Connor

Adv. Services Manager Joan Friedman

Credit Supervisor Patricia H. Ramsey Manager, Administration/Conventions

Lynne Kalish Sales Assistant Evelyn Ploch Secretary Gloria DeMaio

Editorial Offices 12230 Wilkins Ave., Rockville, MD 20852, 800-445-6975, cardiologynews@elsevier.com

Advertising Offices 60 Columbia Rd., Building B, Morristown, NJ 07960, 973-290-8200,

fax 973-290-8250 Address Changes Fax change of address (with old mailing label) to 301-816-8736 or e-mail

change to subs@elsevier.com Reprints Call 301-816-8726

POSTMASTER Send changes of address (with old mailing label) to Circulation, Cardiology News, 12230 Wilkins Ave., Rockville, MD

CARDIOLOGY NEWS is published monthly by Elsevier Inc., 60 Columbia Rd., Building B, Morristown, NI 07960, 973-290-8200, fax 973-290-8250. ©Copyright 2005, by Elsevier Inc.



